The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 939 GLP-1 Medications articles
A new study in BMC Pharmacology and Toxicology uncovers critical subgroup differences in tirzepatide adverse events, showing higher GI intolerance in elderly patients and varied risks based on comorbidities. These insights highlight the need for tailored dosing in type 2 diabetes and obesity treatment. Understand how to balance benefits and risks effectively.
Zydus Lifesciences is set to launch affordable semaglutide injections in India right on patent expiry, targeting the growing Type 2 diabetes and obesity crisis. With innovative reusable pens under brands like SEMAGLYN, MASHEMA, and ALTERME, the company aims to cut costs and improve patient adherence. This move could transform access to GLP-1 therapy for millions.
Comedian Tanmay Bhat recently opened up about his disappointing experience with GLP-1 medications, reporting zero appetite suppression despite using them for weight management. He attributes this to a BDNF gene variant affecting satiety signaling, sparking discussions on genetic factors in treatment response. While many see benefits from drugs like semaglutide and tirzepatide, Bhat's story highlights why results vary.
Semaglutide-based weight-loss drugs like Ozempic and Wegovy are set for a price revolution in India, with generics launching after patent expiry on March 20, 2026, potentially halving costs. Domestic giants like Sun Pharmaceutical and Dr. Reddy's are gearing up to make these GLP-1 therapies more affordable amid rising obesity rates. This shift could transform access to effective treatments for diabetes and weight management.
Alexis Ioane hesitated before starting tirzepatide, a GLP-1 medication, but two months in, she's shed pounds, gained energy for her kids, and cleared her mind. While GLP-1s like Ozempic and Wegovy promise transformative weight loss, experts caution about mental health effects. Discover the full story on body and mind impacts.
Zydus Lifesciences is set to revolutionize semaglutide access in India with a reusable adjustable pen device after the patent expires on March 20. Brands like SEMAGLYN™, MASHEMA™, and ALTERMET™ promise easier dosing and lower prices around ₹3,500-4,000 per month. This move could expand GLP-1 therapy for Type 2 diabetes and obesity amid rising demand.
Without improved prevention, cardiovascular disease rates in U.S. women could climb from 10.7% in 2020 to 14.4% in 2050, warns the American Heart Association. Rising obesity, diabetes, and high blood pressure are key drivers, especially among younger women and underserved groups. Experts call for urgent action on early detection and lifestyle changes.
New research shows that one night of total sleep deprivation significantly delays the glucagon-like peptide 1 (GLP-1) peak response to breakfast in healthy young men. This finding highlights how sleep loss disrupts key incretin hormones involved in glucose regulation and appetite control. Discover the study's design and what it means for metabolic health.
A new Japanese study reveals that three popular GLP-1 drugs—semaglutide, tirzepatide, and retatrutide—may offer hope for rare genetic obesity linked to MC4R deficiency. In mice models, these drugs led to significant weight loss despite faulty hunger signals. Experts discuss the potential and limitations for human treatment.
